Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Immiticide
2. Melarsomine
3. Rm 340
4. Rm-340
1. Cymelarsan
2. Immiticide
3. Cymelarsen
4. 89141-50-4
5. Melarsomine (dihydrochloride)
6. 9cva716q71
7. 2-n-[4-[bis(2-aminoethylsulfanyl)arsanyl]phenyl]-1,3,5-triazine-2,4,6-triamine;dihydrochloride
8. Melcy
9. Bis(2-aminoethyl) P-((4,6-diamino-s-triazin-2-yl)amino)dithiobenzenearsonite Dihydrochloride
10. Mel Cy
11. Arsonodithious Acid, As-(4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)-, Bis(2-aminoethyl) Ester, Hydrochloride (1:2)
12. N2-(4-(bis(2-aminoethylsulfanyl)arsanyl)phenyl)-1,3,5-triazine-2,4,6-triamine Dihydrochloride
13. Melaminylthioarsenite
14. Rm 110
15. Rm-110
16. Melarsenoxide Cysteamine
17. Schembl526148
18. Unii-9cva716q71
19. Chembl3215666
20. Dtxsid90237545
21. Rm110
22. Hy-138502a
23. Melarsomine Dihydrochloride [mi]
24. Arsonodithious Acid, (4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)-, Bis(2-aminoethyl) Ester, Dihydrochloride
25. Cs-0148514
26. Melarsomine Dihydrochloride [green Book]
27. Q27272369
Molecular Weight | 501.3 g/mol |
---|---|
Molecular Formula | C13H23AsCl2N8S2 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 9 |
Exact Mass | 500.008010 g/mol |
Monoisotopic Mass | 500.008010 g/mol |
Topological Polar Surface Area | 205 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 330 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Melarsomine dihydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Melarsomine dihydrochloride, including repackagers and relabelers. The FDA regulates Melarsomine dihydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Melarsomine dihydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Melarsomine dihydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Melarsomine dihydrochloride supplier is an individual or a company that provides Melarsomine dihydrochloride active pharmaceutical ingredient (API) or Melarsomine dihydrochloride finished formulations upon request. The Melarsomine dihydrochloride suppliers may include Melarsomine dihydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Melarsomine dihydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Melarsomine dihydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Melarsomine dihydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Melarsomine dihydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Melarsomine dihydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Melarsomine dihydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Melarsomine dihydrochloride suppliers with NDC on PharmaCompass.
Melarsomine dihydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Melarsomine dihydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Melarsomine dihydrochloride GMP manufacturer or Melarsomine dihydrochloride GMP API supplier for your needs.
A Melarsomine dihydrochloride CoA (Certificate of Analysis) is a formal document that attests to Melarsomine dihydrochloride's compliance with Melarsomine dihydrochloride specifications and serves as a tool for batch-level quality control.
Melarsomine dihydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Melarsomine dihydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Melarsomine dihydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Melarsomine dihydrochloride EP), Melarsomine dihydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Melarsomine dihydrochloride USP).
LOOKING FOR A SUPPLIER?